Scynexis Inc (SCYX)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Strong 155.276%, gain in Revenues , by the company over the most recent fiscal period
Scynexis Inc recorded fourth quarter of 2022 operating shortfall of $-22.48 millions
Published Apr 02 2023
Goran Soko / CSIMarket.com Contributer
![Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg)
Revenues surged sharply by 155.276 % to $1.52 millions from $0.60 millions in the similar reporting period a year prior and sequentially Revenue decreased by -2.119 % from $1.56 millions.
In the fourth quarter of 2022 earnings season Scynexis Inc reported net deficit of $-14.429 million, instead of deficit of $-29.243 millions in the similar reporting period a year ago.
SCYX announced deficit of $-62.81 millions and Revenues of $5.09 millions in the fiscal 12 Months 2022.
Net deficit per share has widen to $-1.47 from $-1.25 in preceding fiscal year, while Revenue Tumbled by -61.32 % from $13.16 millions a year prior.
Scynexis Inc is expected to report next financial recent numbers on May 01, 2023.